Newborn Foundation and Masimo’s Every Woman Every Child Commitment Reaches 52,000 Babies and 1,000 Health Workers in Rural China and Expands into 5 Additional Countries
UN Headquarters Event highlights the BORN Project at three-year mark, reinforcing a global call-to-action to support universal newborn screening utilizing pulse oximetry as a tool to significantly reduce newborn mortality and drive treatment infrastructure in low resource settings.
– On Tuesday, September 19, Masimo (MASI) and the Newborn Foundation took part in an event at the EWEC Hub at UN Headquarters highlighting their joint commitment to the United Nations’ Every Woman Every Child (EWEC) initiative. The BORN Project commitment has now screened 52,000 newborns across 40 delivery sites in China for critical congenital heart disease (CCHD), pneumonia, and sepsis. In addition, 1,000 health workers and public health staff have now been trained in neonatal pulse oximetry screening through the BORN project, which is also marking its third anniversary.
“Harnessing the Power of Technology and Partnerships to Combat Newborn Mortality” will feature expert panelists from China, the Philippines and the U.S. along with participants from public health, the private sector and NGOs. Ms. Carolyn Reynolds, Vice President for Policy and Advocacy, PATH will moderate the panel with opening remarks from Jay Corless, Senior Advisor to the UN Foundation.
Ms. Xu Xiaochao, National Health and Family Planning Commission of the People’s Republic of China (invited)
Dr. Carmencita Padilla, Chancellor, University of Philippines, Manila and Former Director, Newborn Screening Reference Center, National institutes of Health, Philippines
Dr. Linda Wright, Director (Senior Medical Officer) of the Neonatal Research Network and Special Assistant to the CRMC, NICHD, NIH (retired)
Dr. Yu Jing, Director, Department of Pediatrics, Mianyang Central Hospital, Sichuan, China
Dr. Chen Jia, Department of Pediatrics, Mianyang Central Hospital, Sichuan, China
Ms. Stacey Orsat (Taggert), President, EMEA, Masimo International
Ms. Annamarie Saarinen, CEO, Newborn Foundation
The BORN (Birth Oximetry Routine for Newborns) Project, developed by the Newborn Foundation in partnership with Masimo, deployed Masimo’s iSpO2® Rx smartphone- and tablet-paired pulse oximeters. The project aligns with public health initiatives with the goal of reducing newborn mortality from CCHD, pneumonia, and sepsis in pilot regions. It also provides substantive data to public health officials to demonstrate the importance of investment in sustainable universal newborn screening programs and improved access to follow-up care for fragile babies. The project updates come on the heels of news that the National Health and Family Planning Commission, People’s Republic of China, and the Chinese CDC have convened a formal national committee to establish country-wide implementation and screening protocols for universal newborn pulse oximetry screening.
“The BORN project has provided the first large deployment of smart device-paired pulse oximeters for use on newborns. During our more than 3 years working in China, we’ve developed training and educational tools that are simple to deploy and scale,” said Annamarie Saarinen, CEO of the Newborn Foundation. “It’s been a privilege to partner with clinicians, public health officials and the private sector to bring technologies that save lives within reach for babies.”
The BORN Project is conducted in collaboration with the China Office for Maternal and Child Health Surveillance, the China CDC, the Mianyang Health Bureau. It has been supported by Masimo, the Masimo Foundation, and the London-based Global Innovation Fund.
“We must reframe how healthcare is delivered to the youngest and most fragile patients,” said Joe Kiani, Founder and CEO of Masimo. “The work we are doing is already having a powerful impact in China and beyond. We are proud that Masimo SET®, with its proven clinical accuracy and reliability, is able to help save the lives of many newborns.”
About Newborn Foundation
The Newborn Foundation conducts research, implements programs, and develops technology innovations that save lives and improve health outcomes for the newest, most vulnerable citizens of the world. The Foundation programmatically delivers these solutions to those who need them most and drives policies that integrate with public health initiatives to provide sustainable impact for babies and families.
Masimo (MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,1 improve CCHD screening in newborns,2 and, when used for continuous monitoring with Masimo Patient SafetyNet™* in post-surgical wards, reduce rapid response activations and costs.3,4,5Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,6 and is the primary pulse oximetry at 16 of the top 20 hospitals listed in the 2017-18 U.S. News and World Report Best Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), and more recently, Oxygen Reserve Index™ (ORi™), in addition to SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect™ (MOC-9™) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor, iSpO2® pulse oximeter for smartphones, and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm. @MasimoInnovates | #Masimo
About Every Woman Every Child
Launched in 2010 and led by the UN Secretary-General, the Every Woman Every Child movement aims to intensify national and international commitment and action by governments, the UN, multilaterals, private sector and civil society to keep women’s, children’s and adolescents’ health and wellbeing at the heart of development. As a multi-stakeholder platform to operationalize the Every Woman Every Child Global Strategy for Women’s, Children’s and Adolescents’ Health, the movement mobilizes partnerships and coordinated efforts across sectors to ensure that all women, children and adolescents not only survive, but also thrive to help transform the world. Since 2015, 62 country and around 150 multi-stakeholder commitments have been pledged in support of the EWEC Global Strategy, totaling nearly US$30 billion to deliver on the promises of a sustainable future for all. More information is available at http://www.everywomaneverychild.org.